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Antipsychotics are recommended for the treatment of impulsive dyscontrol and cognitive perceptual symptoms of borderline
personality disorder (BPD). Three reports supported the eﬃcacy of oral risperidone on BPD psychopathology. Paliperidone ER
is the metabolite of risperidone with a similar mechanism of action, and its osmotic release reduces plasmatic ﬂuctuations and
antidopaminergic eﬀects. The aim of this study is to evaluate eﬃcacy and safety of paliperidone ER in BPD patients. 18 outpatients
with a DSM-IV-TR diagnosis of BPD were treated for 12 weeks with paliperidone ER (3–6mg/day). They were assessed at baseline,
week 4, and week 12, using the CGI-Severity item, the BPRS, the HDRS, the HARS, the SOFAS, the BPD Severity Index (BPDSI),
and the Barratt Impulsiveness Scale (BIS-11). Adverse events were evaluated with the DOTES. Paliperidone ER was shown to
be eﬀective and well tolerated in reducing severity of global symptomatology and speciﬁc BPD symptoms, such as impulsive
dyscontrol, anger, and cognitive-perceptual disturbances. Results need to be replicated in controlled trials.
1.Introduction
Borderline personality disorder (BPD) is characterized by a
pervasivepatternofinstability ininterpersonal relationships,
self-image, and aﬀects as well as impulsive dyscontrol that
beginsbyearlyadulthoodandappearsinavarietyofcontexts
[1].
Although psychotherapy plays a signiﬁcant role in the
treatment of BPD, focusing on maladaptive personality traits
and interpersonal relationship patterns, pharmacotherapy
is indicated by the treatment guidelines of the American
Psychiatric Association [2, 3] to manage vulnerability traits,
state symptoms, and acute relapses.
The availability of second-generation antipsychotics with
a favourable tolerability proﬁle has oﬀered recent treatment
options in the management of BPD patients. In particular,
atypical antipsychotics are associated with fewer extrapyra-
midal adverse eﬀects, a lower risk of tardive dyskinesia, and
an improvement in cognitive functions [4–6].
Newer antipsychotics promise to be also more eﬃcacious
than traditional neuroleptics, probably due to their dual
mechanism of action, targeting dysfunctions of both sero-
tonergic and dopaminergic systems. These drugs produce
their eﬀects primarily on cognitive perceptual disturbances,
such as transient paranoid or dissociative symptoms but also
on symptoms of depression, anxiety, impulsivity, and aggres-
siveness.
Three reports supported the eﬃcacy of oral risperidone
on a large spectrum of BPD psychopathology, including af-
fective instability, disturbed relationships, impulsivity, ag-
gressiveness, hostility, and cognitive-perceptual impairment
[7–9]. Paliperidone ER (9-hydroxyrisperidone) is a benzis-
oxazole derivative and the main active metabolite of risperi-
done. The eﬃcacy and tolerability proﬁle of this molecule is
modulated both by drug-membrane interaction and drug-
receptor action [10]. Paliperidone is an antagonist at do-
pamine receptor type 2 and serotonin receptor subtype 2A,
with a greater aﬃnity for 5HT2A receptor blockade relative
to D2 receptor blockade. This drug has also some aﬃnity for
H1-histaminergic receptors and for α1-a n dα2-adrenergic
receptors, whereas it lacks signiﬁcant interactions with mus-
carinic receptors and with β1- and β2-adrenergic receptors
[11–13]. Paliperidone does not undergo signiﬁcant hepatic
metabolism and is unlikely to induce drug-drug interactions2 Depression Research and Treatment
[14–17]. Some authors suggested that paliperidone plays a
predominant role in the increase of prolactinemia induced
by risperidone [18, 19]. In fact, paliperidone was reported to
rise prolactin to a higher serum level than risperidone [15,
20–22]. This issue is still debated, and other authors found
that paliperidone and risperidone produced the same in-
crease of prolactinemia over a period of 6 days [23].
Paliperidone extended release(ER) is compounded using
osmotic-controlled dose-release system, a technology that
reduces plasma level ﬂuctuations of the immediate-release
formulation [24–26]. This mechanism is expected to provide
several advantages: a stable plasmatic level allows to avoid
initial dosage adjustments and lowers the risk of antido-
paminergic adverse eﬀects. Another beneﬁt is represented by
once-daily administration, that simpliﬁes treatment regimen
and may improve patients’ adherence.
Several clinical trials evaluated eﬀectiveness of paliperi-
done ER in treating schizophrenia [15, 22, 27, 28]. In par-
ticular, recent studies ascertained signiﬁcant improvements
in positive symptoms, negative symptoms, depression and
anxiety, uncontrolled hostility/excitement, and disorganized
thoughts [27, 29]. At the moment, no data regarding the use
of paliperidone ER in the treatment of personality disorders
have been published.
The present paper is a pilot study with the aim of testing
the eﬃcacy and tolerability of paliperidone ER in patients
with borderline personality disorder.
2.MaterialsandMethods
Consecutive outpatients aged between 18 and 60 years, who
received a diagnosis of borderline personality disorder, were
included in this study. Patients attended the Service for Per-
sonality Disorders, Unit of Psychiatry 1, Department of Neu-
rosciences, University of Turin, Italy. Diagnosis of borderline
personality disorder was made by an experienced clinician
(S.B.) using DSM-IV-TR criteria [1] and performing the
Structured Clinical Interview for DSM-IV Axis II Disorders
[30].
Patients were required to fulﬁl exclusion criteria: a life-
time diagnosis of dementia, delirium, or other cognitive dis-
orders; schizophrenia or other psychotic disorders; bipolar
disorders; a co occurring major depressive episode; sub-
stance/alcohol abuse in the last six months; hyperprolactine-
mia at baseline.
Administration of psychotropic medications and/or psy-
chotherapy in the three months before recruitment was ex-
cluded too.
Female patients in childbearing age were excluded if they
were not using adequate birth control methods (according to
the judgment of the clinician).
Each patient participated voluntarily in the study after
providing a written informed consent. Declaration of Hels-
inki guidelines were followed, and approval by local Ethics
Committee was obtained.
Patients included in the study were treated for 12 weeks
with open-label paliperidone ER 3–6mg/day. No other psy-
chotropic drug or psychological intervention was allowed
during the trial.
Participants in the study were repeatedly assessed (at
baseline, week 4, and week 12) using the following assess-
ment instruments:
(1) the Clinical Global Impression Scale-Severity item
(CGI-S) [31];
(2) the Brief Psychiatric Rating Scale (BPRS) [32];
(3) the Hamilton Depression Rating Scale (HAM-D)
[33];
(4) the Hamilton Anxiety Rating Scale (HAM-A) [34];
(5) the Social Occupational Functioning Assessment
Scale (SOFAS) [35];
(6) the Barratt Impulsiveness Scale-version 11 (BIS-11)
[36];
(7) the Borderline Personality Disorder Severity Index
(BPDSI) [37].
The BPDSI is a semistructured clinical interview assessing
frequency and severity of BPD-related symptoms. The inter-
view consists of eight items scored on 10-point frequency
scales (0 = never; 10 = daily), including “abandonment”,
“interpersonal relationships”, “impulsivity”, “parasuicidal
behavior”, “aﬀective instability”, “emptiness”, “outbursts of
anger”, “dissociation and paranoid ideation”, and one item
scored on a 4-point severity scale, concerning “identity”.
The BPDSI showed excellent reliability coeﬃcients and good
validity indices according to Arntz et al. [37].
The BIS-11 is a 30-item self-report questionnaire assess-
ing the personality trait of impulsivity on a 4-point Likert
Scale [38]. Higher scores for each item indicate higher levels
of impulsivity. Twelve items are reversescored, in order to
avoid response sets. The BIS-11 showed adequate reliability
and construct validity in both US [39] and Italian [40]s a m -
ples.
Assessment was performed by an investigator (P.B.) who
was unaware of the dosing strategy. Prior to this study, the
interviewer received training sessions on the BPDSI.
Adverse eﬀects were assessed using the Dosage Record
and Treatment Emergent Symptoms Scale (DOTES) [41].
Serumprolactinlevelwasmeasuredatbaseline,afterfour
and twelve weeks of treatment. Blood samples were collected
in fasting patients two hours after they woke up. Hyper-
prolactinemia was deﬁned as a level of serum prolactin ≥
20ng/mL in males and ≥ 25ng/mL in females [42, 43]. Body
weight was measured at baseline and endpoint. Weight gain
at least 7% of baseline was considered signiﬁcant [44].
Statistics were performed on the scores of each rating
scale with the analysis of variance (ANOVA) for repeated
measures with Bonferroni correction for multiple com-
parisons (software system SPSS, version 17.0, SPSS Inc.,
Chicago,Ill,2008).Pvalueswereconsideredsigniﬁcantwhen
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Table 1: Results of analysis of variance (ANOVA) for repeated measures with Bonferroni correction for multiple comparisons, performed
with rating scales for BPD-related symptoms and social functioning in patients treated with paliperidone ER (N = 14).
Variable Mean SD SE P
CGI severity item score
T0 4.50 0.51 0.12
0.001 T1 4.28 0.46 0.11
T2 3.72 0.46 0.11
BPRS score
T0 42.28 4.92 1.16
0.001 T1 38.28 4.61 1.09
T2 35.11 3.86 0.91
HARS score
T0 18.17 4.20 0.99
0.262 T1 13.83 4.63 1.09
T2 15.50 4.90 1.16
HDRS score
T0 10.50 3.88 0.92
0.120 T1 8.67 2.61 0.62
T2 8.39 2.28 0.54
SOFAS score
T0 48.78 6.26 1.47
0.001 T1 53.06 5.67 1.34
T2 59.33 6.28 1.48
Table 2: Results of analysis of variance (ANOVA) for repeated measures with Bonferroni correction for multiple comparisons, performed
with BPDSI total score and items “abandonment”, “interpersonal relationship”, “identity”, and “impulsivity”.
Variable Mean SD SE P
BPDSI total score
T0 51.94 3.94 1.478
0.001 T1 47.61 4.40 1.632
T2 44.45 3.78 1.423
Abandonment
T0 6.65 1.51 0.36
1.000 T1 6.35 1.41 0.33
T2 6.37 1.58 0.37
Interpersonal relationships
T0 7.18 1.36 0.32
0.750 T1 6.72 1.25 0.30
T2 6.69 1.11 0.26
Identity
T0 2.81 0.75 0.18
1.000 T1 2.79 0.73 0.17
T2 2.83 0.70 0.17
Impulsivity
T0 7.28 0.77 0.18
0.001 T1 6.17 0.89 0.21
T2 5.69 1.14 0.27
3. Results
Initial sample was made of eighteen patients. They were ﬁve
males and thirteen females, with a mean age ±SD = 24.3 ±
5.4. Fourteen patients (77.8%) completed the trial period.
Four patients (1 male and 3 females, 22.2%) dropped out
in the ﬁrst four weeks of treatment: three patients due to
noncompliance, one female patient for hyperprolactinemia.
The fourteen patients who completed the trial had a mean
age of 25.2 ± 4.9 years; they were four males and ten females.
The mean ± SD daily dose of paliperidone ER was 4.8 ±
1.5mg/day.
Results of ANOVA with Bonferroni correction applied to
rating scales scores are reported in Tables 1, 2,a n d3.
A statistically signiﬁcant improvement was found for
CGI severity item (P = 0.001), BPRS mean score (P = 0.001),
SOFAS mean score (P = 0.001), BIS-11 mean score (P =
0.005), BPDSI total score (P = 0.001), and items “impul-
sivity” (P = 0.001), “outbursts of anger” (P = 0.01), and
“dissociative symptoms/paranoid ideation” (P = 0.002). On
the contrary, there were no signiﬁcant changes of HAM-D
and HAM-A mean score and BPDSI items “abandon-
ment,”“interpersonalrelationships,”“identity,”“parasuicidal
behaviour,” “aﬀective instability,” and “emptiness.”
As far as paliperidone tolerability is concerned, only one
case of severe side eﬀect (hyperprolactinemia) inducing
treatment discontinuation was observed in the initial group
of eighteen subjects (5.6%). Adverse eﬀects recorded in the
ﬁnal sample of fourteen patients were mild to moderate and
includedinsomnia(n=3,21.4%),gastrointestinalsymptoms
(n = 2, 14.3%), agitation (n =1, 7.1%), and extrapyramidal
symptoms (tremor) (n = 1, 7.1%). Six patients (42.9%) had4 Depression Research and Treatment
Table 3: Results of analysis of variance (ANOVA) for repeated measures with Bonferroni correction for multiple comparisons, performed
withBPDSIitems“parasuicidalbehaviour,”“aﬀectiveinstability,”“emptiness,”“outburstsofanger,”and“dissociationandparanoidideation”
and with BIS-11 score.
Variable Mean SD SE P
Parasuicidal behaviour
T0 3.46 2.05 0.48
0.101 T1 2.78 2.03 0.48
T2 2.08 1.53 0.36
Aﬀective instability
T0 5.19 1.26 0.30
0.083 T1 4.54 0.87 0.20
T2 4.42 0.86 0.20
Emptiness
T0 6.41 1.73 0.41
1.000 T1 6.22 1.62 0.38
T2 6.45 1.43 0.34
Outbursts of anger
T0 7.38 0.60 0.14
0.01 T1 6.77 0.72 0.17
T2 6.38 1.05 0.25
Dissociation and paranoid ideation
T0 6.36 1.14 0.27
0.002 T1 5.98 1.04 0.25
T2 4.84 1.18 0.28
BIS score
T0 71.17 7.79 1.83
0.005 T1 65.17 6.31 1.49
T2 62.28 6.43 1.52
at least one adverse eﬀect during treatment period. No cases
of signiﬁcant weight gain (≥7% of baseline) were recorded.
Mean weight gain ± SD was 0.7 ± 0.8kg.
4. Discussion
Findings of this pilot study of paliperidone ER in patients
with borderline personality disorder showed signiﬁcant clin-
ical and functional improvements, as measured with CGI
severity item, BPRS, SOFAS, Barratt Impulsiveness Scale,
BPDSI total score, and items “impulsivity,” “outbursts of
anger,” and “dissociative symptoms/paranoid ideation”.
Because of the lack of trials of paliperidone in the treat-
ment of BPD, these results can only be compared with data
concerning the eﬀects of other second-generation antipsy-
chotics in this personality disorder. A particular interest is
raised by clinical trials of risperidone, a drug with a chemical
structure very similar to paliperidone (actually paliperidone
is the active metabolite of risperidone).
The signiﬁcant changes of the rating scale scores after
treatment, in particular the reduction of the CGI-S, BPRS,
and total BPDSI scores and the increase of the SOFAS score,
indicated that paliperidone ER was eﬃcacious on a large
spectrum of BPD psychopathology. The improvement of
global symptomatology and social functioning was reported
by previous open and controlled studies concerning BPD
treatment with atypical antipsychotics, such as risperidone
[8, 45], clozapine [46, 47], olanzapine [48, 49], quetiapine
[50–56], and aripiprazole [57–60].
In addition to the improvement of global psychopathol-
ogy, paliperidone ER produced in our patients signiﬁcant
eﬀects on speciﬁc symptom dimensions, such as dyscontrol
ofimpulsivityandcognitiveperceptualdistortions.Measures
with the clinician-rated BPDSI and the self-report BIS-11
were concordant and indicated that paliperidone was eﬀec-
tive on impulsive-behavioral dyscontrol symptoms and out-
bursts of anger. Eﬃcacy of second generation antipsychotics
on this cluster of symptoms was already reported by several
trials of olanzapine [48, 61, 62] and quetiapine [50–53,
55, 56]. Data concerning the eﬀect on impulsivity of other
antipsychotics are less consistent. This eﬀect was never
reported in trials of clozapine, and it was found in two pilot
studies of risperidone [9, 45] and in one pilot study of ari-
piprazole in treatment refractory BPD patients [60]. Con-
trolled trials of these two drugs did not list improvement of
impulsivebehaviorsamongtheirﬁndings[7,58].Discordant
data on this issue, particularly concerning risperidone, sug-
gest the need to replicate our initial data on paliperidone,
before drawing any conclusion for clinical practice.
Measures with the BPDSI item “dissociation and para-
noid ideation” in our sample provided initial evidence that
paliperidone ER was eﬀective in treating cognitive and per-
ceptualdisturbances,suchasideasofreference,illusions,and
dissociative symptoms. The eﬃcacy of second-generation
antipsychotics on cognitive and perceptual symptoms was
considered in rather few studies of BPD patients. It was re-
ported in several trials with clozapine [46, 47, 63], in two
studieswithrisperidone[7,9],onewitholanzapine[64],one
with ziprasidone [65], and one with aripiprazole [60]. Fur-
ther investigations are needed to conﬁrm this antipsychotic
eﬀect in BPD.
Concerning tolerability, adverse eﬀects in the ﬁnal
sample of BPD patients were insomnia, gastrointestinal
disturbances, agitation, and extrapyramidal symptoms. Side
eﬀects were mild to moderate in severity. Only one caseDepression Research and Treatment 5
of hyperprolactinemia induced treatment discontinuation.
It is noticeable that we found a low incidence of hyperpro-
lactinemia, compared with previous reports in patients with
schizophrenia [20–22, 66]. No cases of signiﬁcant weight
gain were recorded, in contrast with a recent estimate of
8% in patients with schizophrenia or bipolar disorder [44].
A possible explanation for these diﬀerences is that we used
lowtomoderatedosesofpaliperidone(3–6mg/day).Usually,
doses of paliperidone in patients with schizophrenia were
higher, and some authors retained that hyperprolactinemia
induced by paliperidone was dose related [21, 67]. The pat-
tern of side eﬀects in our sample was generally concordant
with investigations of paliperidone in the treatment of schiz-
ophrenia [15, 27, 29, 67–69].
5. Conclusions
Initial ﬁndings were promising and indicated that low to
moderate doses of the new antipsychotic paliperidone ER
were eﬃcacious in reducing severity of global symptomatol-
ogy and social impairment and in treating two speciﬁc clus-
ters of BPD symptoms, impulsive behavioral dyscontrol, and
cognitive-perceptual disturbance. The level of tolerability
recorded in our patients was favourable, with low incidence
of hyperprolactinemia.
Limitations of the present study were the small sample
size and the lack of a control group. However, this paper was
aimedtoprovideinitial dataontheuseofpaliperidone ERin
BPDtreatmentandpromotelargertrialswithadouble-blind
controlled design.
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